Tenofovir and bone health.

  title={Tenofovir and bone health.},
  author={Philip M. Grant and Aoife G. Cotter},
  journal={Current opinion in HIV and AIDS},
  volume={11 3},
PURPOSE OF REVIEW With continued improvements to the antiviral efficacy and tolerability of antiretroviral therapy, long-term safety of antiretroviral therapy has become paramount. Low bone mineral density and fragility fractures are more common in HIV-infected individuals than in the general population. The aims of this review are to describe potential mechanisms underlying the adverse effects of tenofovir on bone, clinical studies of tenofovir disoproxil fumarate (TDF) and bone, and more… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 13 extracted citations

Emtricitabine + tenofovir alafenamide for the treatment of HIV.

Expert opinion on pharmacotherapy • 2017
View 9 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 54 references

Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss.

Biochemical and biophysical research communications • 2010
View 10 Excerpts
Highly Influenced

Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2015

Similar Papers

Loading similar papers…